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Accepted 20 February 2012AbstractResponse to platinum retreatment in recurrent epithelial ovarian cancer is related to the platinum-free interval (PFI). The recommended and
most accepted chemotherapy in the treatment of platinum-sensitive (PFI > 6 months) recurrence is platinum-based combination regimens.
Patients with a PFI of 6e12 months are often considered partially platinum-sensitive (PPS) because lower response rates to subsequent platinum
retreatment have been identified. Controversies and uncertainties still exist in this population of patients regarding the best treatment and the
most effective therapeutic agents. It is proposed that extending the PFI with non-platinum agents may enhance the response to and the outcome
of subsequent rechallenge with platinum. In this review, we discuss the treatment for PPS recurrent ovarian cancer and the possible clinical
significance of extending PFI with intent to improve the medical care of PPS recurrence.
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The standard upfront treatment for epithelial ovarian cancer
consists of maximal cytoreductive surgery followed by adju-
vant chemotherapy with platinumetaxane combination
regimen. Although response rates (RRs) are in the range of
70e80%, the majority of these patients will eventually relapse
and are then deemed incurable. With the increasing numbers
of available therapies after recurrence, progression free
survival (PFS) after first-line therapy has not increased, but
overall survival (OS) is now longer [1]. Upon recurrence, most
physicians’ choice of second-line chemotherapy is guided by
the duration of response to the prior platinum-based chemo-
therapy, that is, platinum-free interval (PFI). According to the
data reported about 20 years ago, the probability of response to* Corresponding author. Department of Obstetrics and Gynecology, Mackay
Memorial Hospital, Number 92, Section 2, Chung-Shan North Road, Taipei
City 104, Taiwan.
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http://dx.doi.org/10.1016/j.tjog.2012.07.003retreatment with platinum or even non-platinum chemothera-
peutic agents in recurrent ovarian cancer (ROC) depends on
the PFI. The longer the PFI, the better RR can be expected
[2e9]. The prognosis is poor for patients who progress during
treatment (platinum-refractory) or for those whose disease
recurs within 6 months (platinum-resistant). Patients with
a PFI more than 6 months are thought to be platinum-sensitive
so that platinum-based combination chemotherapy is recom-
mended. However, in this group, patients with a PFI of 6e12
months are often considered partially platinum-sensitive (PPS)
because the RR to subsequent platinum retreatment has been
reported to be only 25e30%, which is obviously lower than
that in patients who are thought to be definite platinum-
sensitive (PFI of more than 12 months) [10e12]. Actually,
controversies and uncertainties still exist in this population of
patients regarding the best treatment and the most effective
therapeutic agents. In this article, we review the treatment
options for PPS recurrence and discuss the significance of
using non-platinum agents to extend the PFI in improving the
outcome.cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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principle as those with definite platinum-sensitive
relapse?In platinum-sensitive ROC, platinum-based chemotherapy
is recommended and has been shown to be superior to plat-
inum monotherapy in several phase III trials. However, theses
studies usually did not report detailed or separate data for the
PPS subgroup and should be interpreted with caution. Results
of these clinical trials are summarized in Table 1.
The ICON4 AGO OVAR 2.2 phase III trial compared
paclitaxel plus a platinum-based regimen (paclitaxel plus
carboplatin in 80%) with conventional platinum-based
chemotherapy in 802 women with ROC and a PFI of at least
6 months. The platinumetaxane regimen was associated with
an improved RR (66% vs. 54%, p ¼ 0.06), improved PFS (12
vs. 9 months; Hazard ratio (HR) ¼ 0.76, p ¼ 0.0004), and
improved OS (29 vs. 24 months; HR ¼ 0.82, p ¼ 0.02). When
the subgroup of patients with a PFI of 6e12 months was
evaluated, the impact of combination therapy versus conven-
tional platinum therapy on PFS seemed to be maintained, but
the effect on OS appeared to be less when compared with
those with a PFI of >12 months. However, the difference was
not statistically significant [13e15]. In a recent retrospective
study, a group of 39 patients who had ROC with a PFI S6
months were evaluated, and all of them received carboplatin
and paclitaxel regimen for treatment of platinum-sensitive
recurrence [16]. The authors found that the objective RR
was higher in the subgroup of patients with a PFIS12 months
(RR 86%) than that of the PFI 6e12 months subgroup (RR
68%) ( p ¼ 0.05). It was therefore concluded that reintro-
duction of carboplatin and paclitaxel should be recommended
only in patients with a PFI of at least 12 months, and it would
need more efforts to define the most optimal treatment for
patients with PPS disease.Table 1
Randomized clinical trials assessing combination regimens for second-line treatme
Study ICON4 AGO OVAR 2.2 [13] AGO OVAR 2
Experimental arm (E) Paclitaxel þ Carboplatin Gemcitabine þ
Control arm (C) Carboplatin Carboplatin
Patient number (E vs. C) 392 vs. 410 178 vs. 178
Distribution based on PFI
PFI < 6 mo 0 0.5% vs. 0%
PFI 6e12 mo 23% vs. 27% 39.9% vs. 39.9
PFI > 12 mo 77% vs. 73% 59.6% vs. 60.1
Efficacy results (total platinum-sensitive population/subgroup PFI 6e12 mo)
Response rate 6.6%#/NR 47.2%#/NR
PFS, median (mo) 13#/NR 8.6#/7.9#
Overall survival (mo) 29#/NR 18*/NR
Conclusion Combination therapy
significantly improves PFS
and OS. Data for subgroup
of PFI 6e12 mo not reported
separately (maintained effect
on PFS but less positive on OS;
difference of effects on PFS and
OS not reached significantly)
Combination t
significantly im
not only in tot
sensitive popu
also in the sub
of PFI 6e12 m
NR ¼ not reported; OS ¼ overall survival; PFI ¼ progression free interval; PFS ¼
# Significantly different when compared to control arm; * Not significantly diffIn the AGO OVAR 2.5 phase III trial, 356 patients with
platinum-sensitive disease (PFI 6 months) were randomized
to the treatment of either carboplatin alone or carboplatin plus
gemcitabine combination regimen. In overall population, PFS
was significantly longer (8.6 vs. 5.8 months; HR 0.72;
p ¼ 0.0031) and RR was significantly higher (47.2% vs.
30.9%, p ¼ 0.0016) in patients receiving combination
regimen. OS was similar in the two groups (18.0 vs. 17.3
months), but the study was not powered for an OS endpoint.
Of note, the study demonstrated improved PFS in patients with
a PFI <12 months (7.9 vs. 5.2 months; HR 0.69; p ¼ 0.0311)
[14,17]. However, relative to therapy with taxanes, gemcita-
bine plus carboplatin exhibited a preferable toxicity profile
because greatly diminished neuropathy and alopecia had been
shown, which are of importance for the affected women,
making gemcitabine plus carboplatin another treatment option
for patients with platinum-sensitive ROC.
In the CALYPSO (Caelyx in Platinum Sensitive Ovarian
patients) randomized, multicentric, phase III non-inferiority
trial, a total of 976 patients who relapsed more than 6
months after first- or second-line platinum and taxane-based
therapies were randomly assigned to carboplatin plus pegy-
lated liposomal doxorubicin (PLD) (CD arm) or carboplatin
plus paclitaxel (CP arm) for at least 6 cycles. The non-
inferiority PFS primary endpoint was not only met, but CD
was associated with a statistically significant improvement in
PFS over CP (11.3 vs. 9.4 months; HR ¼ 0.82; p ¼ 0.005).
Furthermore, severe toxicities and bothersome side effects
associated with CPdincluding carboplatin hypersensitivity
reactions, peripheral neuropathy, and alopeciadwere mark-
edly reduced with CD regimen [18e22]. The benefits
observed in the whole CALYPSO population for CD could
also be noted in the PPS subgroup (median PFS ¼ 9.4 months
in the CD arm vs. 8.8 months in the CP arm), which comprised
35% of the 976 patients. In addition, the risk reduction ofnt of patients with platinum-sensitive relapsed ovarian cancer.
.5 [17] CALYPSO [18,23,25] OVA-301 [45,47]
Carboplatin PLD þ Carboplatin PLD þ Trabectidin
Paclitaxel þ Carboplatin PLD
486 vs. 507 337 vs. 335
0 35% vs. 35%
% 35% vs. 36.1% 37% vs. 28%
% 65% vs. 63.9% 29% vs. 37%
NR/39% 35.2%#/NR
11.3#/9.4# 9.2#/7.4#
Immature data 22.4*/23#
herapy
proves PFS
al platinum-
lation but
group
o.
Combination therapy
significantly improves PFS
not only in total
platinum-sensitive
population but also in the
subgroup of PFI 6e12
Combination therapy
significantly improves
PFS in platinum-sensitive
patients with a more
pronounced positive impact
on PFI 6e12 mo subgroup
progression free survival; PLD ¼ pegylated liposomal doxorubicin.
erent when compared to control arm.
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subgroup vs. 18% in the overall population) [23e25].
Although non-platinum single chemotherapeutic agents,
including topotecan and PLD, are most commonly used in
platinum-resistant disease, they have been shown to have
better RR in the setting of platinum-sensitive disease. As
a matter of fact, these drugs have been approved by the Food
and Drug Administration in the treatment of both platinum-
sensitive and platinum-resistant ROC [26]. In patients with
a PFI of >6 months, although topotecan and PLD had similar
RR, median PFS (28.9 months for PLD vs. 23.3 months for
topotecan, p ¼ 0.037) and OS (108 vs. 71.1 weeks, p ¼ 0.008)
significantly favored PLD [27,28]. Further analysis demon-
strated that the survival benefit was more prominent in patients
with a PFI of 6e12 months (n ¼ 122; HR ¼ 1.58; p ¼ 00.021)
than in patients with a PFI of >12 months (n ¼ 97;
HR ¼ 1.15; p ¼ 0.057) [29].
Based on these studies, the UK National Institute for
Clinical Excellence recommends a platinumetaxane combi-
nation or single-agent PLD for the treatment of PPS ROC [30].
On the other hand, the National Comprehensive Cancer
Network recommends using similar treatment regimens
(platinum based) for patients whose disease recurs after >6
months (platinum-sensitive patients) and does not mention
different treatment strategy for PPS relapse, but emphasizes
that no single therapeutic agent should be currently recom-
mended as the treatment of choice for recurrence [31].Can platinum-sensitivity be increased in a partially
platinum-sensitive group by using non-platinum drugs to
defer the reintroduction of platinum to a later time?It has been hypothesized that platinum sensitivity can be
restored by prolonging PFI. In vitro tumor models have shown
that platinum resistance is an unstable, reducible, and perhaps
reversible phenomenon. Treatment with non-platinum drugs to
extend the PFI may make cells sensitive to platinum drugs
again [32]. The results of some retrospective clinical studies or
small series also imply the feasibility of this strategy.
According to the series reported by Kavanagh et al [33], in
which 33 patients with ovarian cancers refractory to plati-
numetaxane combination were treated with single agent tax-
ane at next relapse, followed by single-agent carboplatin once
the disease progressed on a taxane, the RR of carboplatinTable 2
Summary of the SOCRATES study [35].
Group A
Patient number (persons) 282
Definition Platinum as
second-line CT
PFI at the time when receiving second-line CT (mo) 19
Response rate to non-platinum agents d
Median time to platinum retreatment (mo) 19
Response rate to platinum retreatment 74.4%
Mean overall survival (mo) 27.2
PFI ¼ progression-free interval.reintroduction was 21%. However, responses were noted only
in patients with a PFI of at least 12 months and an initial
sensitivity to a taxane. The authors proposed that the finding
may be secondary to taxane therapy that leads to the reversal
of platinum resistance, or the prolonged PFI makes the tumors
lose their resistance to platinum. A more recent retrospective
review, reported by See et al [34], identified 34 patients with
ovarian cancer who had previously progressed on platinum
therapy and were considered platinum resistant or refractory.
The median PFI from the time platinum was last received to
retreatment with carboplatin was 15.2 months. Partial response
was found in two patients (5.9%), while 21 patients (61.7%)
had a stable disease. It seems that patients who have been
deemed platinum resistant may still benefit from platinum
retreatment after a period of treatment with non-platinum
agents.
In order to determine the impact of extending PFI with
intervening non-platinum agents on subsequent platinum
retreatment in platinum-sensitive ROC, Italian investigators in
the SOCRATES study retrospectively identified 428 patients
who had ROC with a PFI of >6 months [35]. The interval
from the end of the first line to relapse was 6e12 months in
164 patients (39.5%) and >12 months in 251 cases (60.5%).
At second line, 282 (65.9%) received platinum (group A),
while 146 (34.1%) received non-platinum chemotherapy
(group B). In the latter group, 67 patients received platinum at
later progression (group B1), while 79 never received platinum
(group B2) (Table 2) [35]. The initial PFI at the time of
receiving second-line chemotherapy was 19, 9.6, and 8.4
months in patients of groups A, B1, and B2, respectively.
Median time to platinum retreatment was 19 and 23.1 months
in patients of groups A and B1, respectively. The RR to the
first platinum received was 74.4% and 57.4% in groups A and
B1, respectively ( p ¼ 0.02). Although the results of SOC-
RATES study made the authors question the hypothesis that
extending the PFI with an intervening non-platinum therapy
improves the RR of a further platinum retreatment, we should
notice the difference in baseline PFI in each group. Actually,
group A (PFI 20 months) represented ROC with PFI >12
months, while group B1 (PFI 9.6 months) and group B2 (PFI
8.4 months) represent ROC patients with PFI 6e12 months.
Patients in the two subgroups had different baseline of PFI and
thus, cannot be compared fairly. Although a better RR was
found in group A, the median OS was similar in group A andB1 B2
67 79
Non-platinum as second-line
CT followed by platinum
as third-line CT
Non-platinum as second-line
CT and platinum never
being used thereafter
9.6 8.4
44.6% 28.8%
23.1 d
57.4% d
26.1 16.8
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B2 was characterized by having the worst RR (28.8%) and
survival (16.8 months).
Currently, an Italian multicentric randomized phase III trial
[Multicenter Italian Trials in Ovarian Cancer group 8 (MITO-
8)] is ongoing and is aimed to test the hypothesis that artificial
prolongation of PFI with a non-platinum treatment will
improve the effectiveness of overall therapy in patients with
ovarian cancer progression occurring 6e12 months after first-
line treatment with a platinum-based regimen (Fig. 1). Patients
will be randomized to receive either PLD monotherapy fol-
lowed by paclitaxelecarboplatin at the next progression or the
reverse (paclitaxelecarboplatin and then PLD monotherapy at
the second progression). The primary endpoint will be OS
[36]. Only when there is solid evidence from prospective
randomized trials can we confirm the benefit of extending PFI
in the treatment of PPS recurrence.Non-platinum agents may be a more effective alternative
to platinum-based regimen in the treatment of patients
with partially platinum-sensitive relapseIn addition to PLD, the combination regimen of PLD and
trabectidin is gaining attention in the treatment of ROC,
especially in the subset of PPS relapse. Trabectedin (Yondelis;
PharmaMar, Colmenar Viejo, Spain) is a synthetic, marine-
derived anticancer agent, originally isolated from the Carib-
bean sea tunicate, Ecteinascidia turbinata. Trabectedin was
initially approved in soft tissue sarcoma by the European
Medicines Agency in 2007, and in combination with PLD for
the treatment of patients with recurrent platinum-sensitive
ovarian cancer in September, 2009. The drug has been
approved in 60 countries worldwide and is being developed for
treating breast and other solid tumors. Trabectedin uniquely
binds covalently to the minor groove of DNA, bends the DNA
toward the major groove, interrupts transcription, and results
in G2-M cell cycle block, leading to apoptosis [9,37e41].
Three phase II studies have demonstrated the activity and
efficacy of single agent trabectidin [42e44]. Furthermore, the
randomized phase III OVA-301 trial (n ¼ 672), whichPatients with ovarian cancer progression occurring 
6-12 months after first-line treatment with a 
platinum-derivative 
Randomization 
Paclitaxel 175 mg/m2 + 
Carboplatin AUC 5 (day 1, 
every 21 days) 
PLD 40 mg/m2 (day 1, every 
28 days) 
PLD 40 mg/m2 (day 1, every 
28 days) 
Cross over at progression 
Paclitaxel 175 mg/m2 + 
Carboplatin AUC 5 (day 1, 
every 21 days) 
Fig. 1. Multicenter Italian Trials in Ovarian Cancer group 8 (MITO-8) study
design.included patients with platinum-sensitive relapse (PFI >6
months) and platinum-resistant recurrence (PFI <6 months)
(but excluded patients who had disease progression during
frontline therapy, that is, platinum-refractory disease),
demonstrated that trabectedin plus PLD combination signifi-
cantly improves PFS (median PFS 7.3 months with trabecte-
din/PLD vs. 5.8 months with PLD; HR ¼ 0.79; p ¼ 0.019) and
overall RR (27.6% for trabectedin/PLD vs. 18.8% for PLD,
p ¼ 0.008) over PLD alone. The toxicity related to trabecte-
din/PLD was acceptable. No difference was found in the
interim analysis for OS (22.4 vs. 19.5 months for PLD,
p ¼ 0.092) [45,46]. In the subgroup analysis for platinum-
sensitive patients, the median PFS was 9.2 and 7.5 months,
respectively (HR ¼ 0.73; p ¼ 0.017) and the RR was 35.3%
and 22.6% ( p ¼ 0.0042), both favoring the trabectidin/PLD
combination. As for OS, a positive trend in favor of the
combination was observed (22.4 vs. 19.5 months, p ¼ 0.0920).
For the platinum-resistant subgroup, there was no difference
regarding RR, PFS, and OS.
In the post-hoc, exploratory, and hypothesis-generating
analysis, the subgroup of patients with a PFI of 6e12 months,
who comprised one-third (n ¼ 214) of the 672 randomized
patients in the OVA-301 trial, were analyzed. Trabectedin/PLD
resulted in a 35% risk reduction of disease progression or death
[HR ¼ 0.65, 95% confidence interval (CI), 0.45e0.92;
p ¼ 0.0152; median PFS 7.4 vs. 5.5 months], and a significant
41% decrease in the risk of death (HR ¼ 0.59; 95% CI,
0.43e0.82; p¼ 0.0015; median survival 23.0 vs. 17.1 months).
The safety of trabectedin/PLD in this subset did not differ from
that of the overall population. Importantly, time from random-
ization to subsequent platinum was significantly longer
(HR¼ 0.64; p¼ 0.0167; median 9.8 vs. 7.9months) for patients
in the trabectedin/PLD combination arm, who also survived
significantly longer after subsequent platinum (HR ¼ 0.63;
p ¼ 0.0357; median 13.3 vs. 9.8 months) [47].
In summary, the OVA-301 trial demonstrated that tra-
bectedin/PLD combination brings in significantly superior
PFS and a positive trend in OS over PLD alone. Benefits
appeared more evident in the platinum-sensitive subset (PFI >
6 months) and even more pronounced in patients with PPS
disease. The investigators postulated that the enhanced
survival benefits with trabectedin/PLD over single agent PLD
in OVA-301, particularly in patients with PPS disease, may be
due to an extension of the PFI which helps in the improvement
of response to subsequent platinum-based therapy [48]. This
hypothesis will be tested in the ongoing phase III prospective,
multicentric, randomized trial, INOVATYON Study (Interna-
tional, Randomized Study in Patients With Ovarian Cancer),
which has started to recruit participants since June 2011, by
the Mario Negri Gynecologic Oncology group (Fig. 2). The
objective is to demonstrate the superiority, in terms of pro-
longed survival, of trabectedin and PLD (regimen evaluated in
OVA-301 trial) versus carboplatin and PLD (regimen evalu-
ated in CALYPSO trial) in patients with advanced and
progressive ovarian cancer 6e12 months after completion of
first-line treatment with platinum-based chemotherapy [49].
At disease progression, the trabectidin/PLD arm is allowed to
Fig. 2. International, Randomized Study in Patients with Ovarian Cancer
(INOVATYON) Study design.
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subsequent therapy of the carboplatin/PLD arm will be based
on investigator discretion. This would allow the prospective
evaluation of the effect of PFI extension with a non-platinum
combination on response to subsequent platinum.
Conclusion
Current recommendations for the treatment of ROC with
a PFI 6e12 months are the same as those for a PFI of >12
months, but the best therapy option for the PPS disease remains
to be determined. Although platinum-based combinations are
recommended, the possibility of unsatisfactory response is
frequently expected because it has been observeddand thus
believed by most gynecology oncologistsdthat the response to
platinum retreatment is closely related to the duration of PFI.
The emergence and use of non-platinum agents, such as
PLD, topotecan, or trabectidin, may help improve the care of
this subpopulation for two potential reasons. One would be
that non-platinum agents may have better treatment efficacy
than platinum-based therapy in the PPS subset. The other
possible benefit might be due to the prolongation of PFI,
which is believed to be capable of reversing platinum resis-
tance, or increasing sensitivity to and response to subsequent
platinum retreatment. Preclinical or retrospective clinical
studies as well as some small series have provided evidence on
the feasibility and potential benefits of this strategy. The data
from OVA-301 trial are encouraging because they have vali-
dated trabectidin plus PLD combination as a new valuable and
promising treatment option in the treatment of relapsed
ovarian cancer, especially for patients with a PFI of 6e12
months. However, only after evidences from prospective
studies, such as MITO-8 study or INOVATYON study, have
been made available can we confirm the hypothesis.
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